BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 31209816)

  • 1. Influence of Different Gonadotropin-releasing Hormone Agonist Administration Methods on Pregnancy Outcomes of Patients Undergoing In-vitro Fertilization-embryo Transfer.
    Wu L; Ren XL; Chen W; Huang B; Zhou YF; Jin L
    Curr Med Sci; 2019 Jun; 39(3):437-441. PubMed ID: 31209816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
    Xiao ZN; Peng JL; Yang J; Xu WM
    Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose GnRH antagonist protocol is as effective as the long GnRH agonist protocol in unselected patients undergoing in vitro fertilization and embryo transfer.
    Huang SY; Huang HY; Yu HT; Wang HS; Chen CK; Lee CL; Soong YK
    Taiwan J Obstet Gynecol; 2011 Dec; 50(4):432-5. PubMed ID: 22212313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of gonadotropin releasing hormone agonist long protocol and gonadotropin releasing hormone antagonist protocol in infertile women].
    Ren Y; Yang S; Yang R; Li R; Chen XN; Wang HY; Ma CH; Liu P; Qiao J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Dec; 45(6):877-81. PubMed ID: 24343066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the effects of three luteal phase support protocols with estrogen on in vitro fertilization-embryo transfer outcomes in patients on a GnRH antagonist protocol.
    Scheffer JB; Scheffer BB; Carvalho RF; Aguiar AP; Lozano DHM; Labrosse J; Grynberg M
    JBRA Assist Reprod; 2019 Aug; 23(3):239-245. PubMed ID: 30875186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study on the pregnancy outcomes of in vitro fertilization-embryo transfer between long-acting gonadotropin-releasing hormone agonist combined with transvaginal ultrasound-guided cyst aspiration and long-acting gonadotropin-releasing hormone agonist alone.
    Guo YH; Lu N; Zhang Y; Su YC; Wang Y; Zhang YL; Sun YP
    Contemp Clin Trials; 2012 Nov; 33(6):1206-10. PubMed ID: 22820320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical outcomes between the depot gonadotrophin-releasing hormone agonist protocol and gonadotrophin-releasing hormone antagonist protocol in normal ovarian responders.
    Xia M; Zheng J
    BMC Pregnancy Childbirth; 2021 May; 21(1):372. PubMed ID: 33975553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cumulative live birth rates between GnRH-agonist long and GnRH-antagonist protocol in one ART cycle when all embryos transferred: real-word data of 18,853 women from China.
    Yang J; Zhang X; Ding X; Wang Y; Huang G; Ye H
    Reprod Biol Endocrinol; 2021 Aug; 19(1):124. PubMed ID: 34384445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
    Kim CH; Ahn JW; You RM; Kim SH; Chae HD; Kang BM
    J Reprod Med; 2014; 59(1-2):63-8. PubMed ID: 24597289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
    Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y
    Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Endometrium Thickness on Clinical Outcomes in Luteal Phase Short-Acting GnRH-a Long Protocol and GnRH-Ant Protocol.
    Zhang J; Sun YF; Xu YM; Shi BJ; Han Y; Luo ZY; Zhao ZM; Hao GM; Gao BL
    Front Endocrinol (Lausanne); 2021; 12():578783. PubMed ID: 34079517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.